000			03090cam a2200349 a 4500
003			EG-GiCUC
005			20250223032244.0
008			190413s2018 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.19.05.Ph.D.2018.Wa.F
100	0		_aWalaa Elsayed Mohamed
245	1	0	_aFrequency and prognostic significance of RUNX1 gene amplification in Egyptian pediatric patients with precursor B- cell acute lymphoblastic leukemia / _cWalaa Elsayed Mohamed ; Supervised Shrief Aboulnaga Abuolnaga , Iman Abdelmokhales Sidhom , Shrine Ibrahim Salem
246	1	5	_aمعدل حدوث والمدلول التكهني للتضخيم الجيني رن اكس 1 في الاطفال المصريين المصابين بسرطان الدم الليمفاوي الحاد من نوع الخلايا ب
260			_aCairo : _bWalaa Elsayed Mohamed , _c2018
300			_a157 P. : _bcharts ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology
520			_aPurpose: To evaluate the frequency of intrachromosomal amplification of chromosome 21(iAMP21) in pediatric patients with B-cell precursor acute lymphoblastic leukemia, to study its relation to clinical as well as biological features of the patients and to assess its prognostic significance. Methods: Pediatric patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), who were treated at children cancer hospital Egypt 57357 from the year 2009 to 2011 on St. Jude total study XV protocol were retrospectively screened with ETV6/RUNX1-specific fluorescent in situ hybridization (FISH) probe for the presence of iAMP21. Results: In total, 518 patients were included. iAMP21 was found in 2% of the patients. The median age for iAMP21patients was 6.7 years and the median value of white blood cell count was 6.2 x 10³/mL. None of the patients had Pro-B immunophenotype. About 44% of the patients with iAMP21 had slow early response compared to 17% in the no iAMP21 group (p =0.031). Among iAMP21 patients, those with negative MRD at the end of the induction and received intermediate risk treatment didn't have relapses. On the other hand, 2 out of the 5 patients who received the low risk treatment had relapses despite MRD negativity at the end of the induction. Conclusion: The presence of iAMP21 was related to slow early response to induction treatment and was likely associated with lower RFS compared to patients without iAMP21 (66.7±15.7% v 84.7±1.7%; p=0.205 respectively). So, those patients will benefit from receiving more intensive chemotherapy regimens
530			_aIssued also as CD
653		4	_aBCP-ALL
653		4	_aFISH
653		4	_aIAMP21
700	0		_aIman Abdelmokhales Sidhom , _eSupervisor
700	0		_aShrief Aboulnaga Abuolnaga , _eSupervisor
700	0		_aShrine Ibrahim Salem , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c71432 _d71432